TW201141519A - Anti-HER2 antibodies and compositions - Google Patents

Anti-HER2 antibodies and compositions Download PDF

Info

Publication number
TW201141519A
TW201141519A TW100107086A TW100107086A TW201141519A TW 201141519 A TW201141519 A TW 201141519A TW 100107086 A TW100107086 A TW 100107086A TW 100107086 A TW100107086 A TW 100107086A TW 201141519 A TW201141519 A TW 201141519A
Authority
TW
Taiwan
Prior art keywords
antibody
light chain
her2
variable region
seq
Prior art date
Application number
TW100107086A
Other languages
English (en)
Chinese (zh)
Inventor
Mikkel Wandahl Pedersen
Allan Jensen
Per-Johan Meijer
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of TW201141519A publication Critical patent/TW201141519A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW100107086A 2010-03-04 2011-03-03 Anti-HER2 antibodies and compositions TW201141519A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201070085 2010-03-04
US35413310P 2010-06-11 2010-06-11
US42801410P 2010-12-29 2010-12-29

Publications (1)

Publication Number Publication Date
TW201141519A true TW201141519A (en) 2011-12-01

Family

ID=44541704

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100107086A TW201141519A (en) 2010-03-04 2011-03-03 Anti-HER2 antibodies and compositions

Country Status (5)

Country Link
EP (1) EP2542589A4 (enExample)
JP (1) JP6039428B2 (enExample)
CN (1) CN102884084B (enExample)
TW (1) TW201141519A (enExample)
WO (1) WO2011107957A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883149B2 (en) 2008-09-15 2014-11-11 Yeda Research And Development Co. Ltd. Antibody combinations and use of same for treating cancer
ES2692379T3 (es) * 2010-11-01 2018-12-03 Symphogen A/S Anticuerpos anti-HER3 y composiciones
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
US9040047B2 (en) 2011-05-16 2015-05-26 Yeda Research And Development Co. Ltd. Combinations of anti ErbB antibodies for the treatment of cancer
WO2013164689A2 (en) * 2012-05-02 2013-11-07 Lantto, Johan Humanized pan-her antibody compositions
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
JP6326137B2 (ja) * 2013-11-19 2018-05-16 烟台▲榮▼昌生物工程有限公司Ｒｅｍｅｇｅｎ， Ｌｔｄ． 抗ｈｅｒ２抗体及びその結合体
CN104974261B (zh) * 2014-04-01 2019-06-14 三生国健药业（上海）股份有限公司 重组抗her2/ps双特异性抗体、其制备方法和应用
BR112017011170A2 (pt) * 2014-12-18 2018-02-27 Hoffmann La Roche método para determinar a citotoxicidade dependente do complemento de uma composição
CN106831987B (zh) * 2015-12-04 2020-01-21 浙江大学 一种抗人her2抗体及其编码基因和应用
JP2019525138A (ja) * 2016-06-16 2019-09-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｄｃを誘発する抗体を決定するためのアッセイ法および方法
CA3029003A1 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
CN107137424B (zh) * 2017-05-15 2024-12-17 广州领晟医疗科技有限公司 一种利用正常小鼠建立her2阳性肿瘤的动物模型的方法
IL277049B2 (en) 2018-03-13 2024-02-01 Zymeworks Bc Inc Conjugates of biparatopic anti-HER2 antibody and drug and methods of use
CN109134656A (zh) * 2018-09-12 2019-01-04 四川妙和生物科技有限公司 一种抗her2多克隆抗体
SG11201913540VA (en) * 2019-03-15 2020-10-29 Japanese Found For Cancer Res Anti-Podoplanin Antibody
JP7727549B2 (ja) * 2019-03-22 2025-08-21 セルティス・セラピューティクス・ピーティーワイ・リミテッド 抗ｈｅｒ２結合分子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794128B2 (en) * 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
US7244826B1 (en) * 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
CA2506320A1 (en) * 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
GB0503546D0 (en) * 2005-02-21 2005-03-30 Hellenic Pasteur Inst Antibody
US7498142B2 (en) * 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
EP2331577B1 (en) * 2008-08-29 2017-06-07 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions

Also Published As

Publication number Publication date
WO2011107957A1 (en) 2011-09-09
CN102884084B (zh) 2016-12-07
EP2542589A4 (en) 2013-08-07
EP2542589A1 (en) 2013-01-09
JP2013520984A (ja) 2013-06-10
CN102884084A (zh) 2013-01-16
JP6039428B2 (ja) 2016-12-07

Similar Documents

Publication Publication Date Title
JP6927639B2 (ja) ヒトクローディン−１８．２を結合する抗体およびその使用
TW201141519A (en) Anti-HER2 antibodies and compositions
US8609095B2 (en) Anti-HER2 antibodies and compositions
JP6033783B2 (ja) Ｐａｎ−ｈｅｒ抗体組成物
US10221246B2 (en) Pan-HER antibody composition
CN110790839B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
KR20220042258A (ko) 항 tigit 항체 및 그의 응용
CN113045661B (zh) 新型抗cd4抗体
KR20220121808A (ko) 항-pd-l1/항-b7-h3 다중특이적 항체 및 이의 용도
TW201916890A (zh) 抗ｐｄ－１抗體和抗ｌａｇ－３抗體聯合在製備治療腫瘤的藥物中的用途
WO2021115303A1 (zh) 一种抗Claudin18.2单克隆抗体、其制备方法及用途
KR20210069058A (ko) 항-ox40 항체, 이의 항원-결합 단편 및 약학적 용도
JP2016182135A (ja) 抗ｈｅｒ２抗体および組成物
US20250195645A1 (en) Combination of multispecific molecule and immune checkpoint inhibitor
HK40078463A (en) Anti-claudin18.2 monoclonal antibody, preparation method therefor and use thereof